Pharmbio Korea signs exclusive license agreement of new opioid painkiller with U.S.
Pharmbio Korea(Chairman Bong-Gil Nam) announced on the 14th that the company signed an exclusive license agreement for development and commercialization of Oliceridine, an opioid, intravenous injection being developed, in the Korean market with Trevana, a U.S. biopharmaceutical company.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.